Targeted drug shows promise for rare cancers with cKIT mutation
NCT ID NCT06390826
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 25 times
Summary
This study tests the drug sunitinib in people with advanced cancers that have a specific change in the cKIT gene. Sunitinib works by blocking signals that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. About 10 adults with certain lymphomas, solid tumors, or multiple myeloma that haven't responded to other treatments are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.